



PEMETREXED USE IN PATIENTS WITH STAGE IV LUNG ADENOCARCINOMA WHO UNDERGO THYMIDYLATE SYNTHASE LEVEL INVESTIGATION

Forte Pérez-Minayo, M; Castillo Bazán, E; Bécares Martínez, FJ; Bonilla Porras, M; Panadero Esteban, MI; Toledano Mayoral, G; Tortajada Esteban, EV; Arias Moya, MA; Hernández Segurado, M. Fundación Jiménez-Díaz, Department of Pharmacy. Madrid. Spain.

PURPOSE

Comparison of patients with stage IV lung adenocarcinoma and low levels of TS with those patients that didn't undergo previous studies.

MATERIAL AND METHODS

Retrospective observational study over a three year period (2011-2014)

Patients with stage IV lung adenocarcinoma that were treated with pemetrexed

Patients that have completed treatment **VS.** Patients being followed up (routine determination of TS)

Data collected:

- Age
- Line of treatment
- Cycles received
- ECOG
- Previous treatments
- Progression free survival (PFS)
- Levels of TS



PFS first group: first cycle-disease progression
PFS second group: first cycle-up to date (now in treatment)


RESULTS

31 patients (median age 62 years and median of cycles of pemetrexed received 4)


As first treatment → 13
As second treatment → 13
As third treatment → 3
As fourth treatment → 2

ECOG 0 → 13
ECOG 1 → 15
ECOG 2 → 3

PATIENTS THAT HAVE COMPLETED TREATMENT
n = 21
median PFS = 1,3 months



PATIENTS BEING FOLLOWED UP
n = 10
median stable disease = 6,5 months
(now in treatment)



CONCLUSION

Patients who initiate treatment without previous scoring of TS have worse response to pemetrexed. **TS level determination** is considered an indicator of the **effectiveness** of the treatment..